Coastline Trust Co Reduces Holdings in Zoetis Inc. $ZTS

Coastline Trust Co decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,994 shares of the company’s stock after selling 194 shares during the period. Coastline Trust Co’s holdings in Zoetis were worth $935,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Sage Rhino Capital LLC increased its position in shares of Zoetis by 2.0% in the 2nd quarter. Sage Rhino Capital LLC now owns 7,155 shares of the company’s stock worth $1,116,000 after purchasing an additional 141 shares during the last quarter. Blossom Wealth Management grew its position in Zoetis by 10.1% in the 2nd quarter. Blossom Wealth Management now owns 2,971 shares of the company’s stock worth $463,000 after purchasing an additional 272 shares during the last quarter. LVW Advisors LLC lifted its stake in shares of Zoetis by 43.7% in the 2nd quarter. LVW Advisors LLC now owns 5,876 shares of the company’s stock worth $916,000 after acquiring an additional 1,787 shares during the period. Diversified Enterprises LLC lifted its stake in shares of Zoetis by 10.2% in the 2nd quarter. Diversified Enterprises LLC now owns 1,458 shares of the company’s stock worth $227,000 after acquiring an additional 135 shares during the period. Finally, Townsend Asset Management Corp NC ADV lifted its stake in Zoetis by 7.8% during the second quarter. Townsend Asset Management Corp NC ADV now owns 26,510 shares of the company’s stock valued at $4,134,000 after purchasing an additional 1,921 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $143.52 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $197.51. The company has a market capitalization of $63.61 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 2.30 and a beta of 0.89. The firm’s 50 day moving average is $150.35 and its 200-day moving average is $155.67.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent research reports. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.